Absci Corp (ABSI) Stock Price & Analysis
Absci Corp (ABSI) rose 2.10% to USD 9.01 as of September 8, 2026 at 17:48 UTC, according to Nexqual real-time market data.
ABSI last closed at USD 9.01; the session ranged USD 8.57–9.1 on volume of 1,571,868 shares. Market capitalization is —, with a 52-week range of USD 2.24–12.06 (NMS). Source: Nexqual, September 8, 2026 at 17:48 UTC.
Key Statistics (as of September 8, 2026 at 17:48 UTC)
| Price | USD 9.01 |
|---|---|
| Change | ▲ 2.10% (up) |
| Previous Close | USD 9.01 |
| Open | USD 9.01 |
| Day Range | USD 8.57 – 9.1 |
| 52-Week Range | USD 2.24 – 12.06 |
| Volume | 1,571,868 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ABSI)
Nexqual's technical model rates ABSI "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 17:48 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.3 (neutral) |
| vs SMA50 | Below (USD 9.21) |
| MACD | 0.03 (positive) |
From Absci Corp's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Advancing AI drug creation by leveraging our proprietary data: We use data generated through our programs and design campaigns to support the continued development of our AI models.
- Intellectual Property We strive to protect and enhance the proprietary technology, inventions, know-how and improvements that we believe are commercially important to our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties, that cover our Integrated Drug Creation platform, as well as our internally developed programs.
- Biologics License Application (BLA) Submission and Review Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a B
- Our Integrated Drug Creation Platform Absci is a clinical-stage, AI-native biopharmaceutical company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RXRX | Recursion Pharmaceuticals, Inc. | USD 3.49 | ▲ 1.31% |
| PRME | Prime Medicine, Inc. | USD 3.53 | ▼ 4.85% |
| RLAY | Relay Therapeutics, Inc. | USD 18.89 | ▼ 0.63% |
| SANA | Sana Biotechnology, Inc. | USD 3.65 | ▼ 6.91% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 3.22 | ▲ 4.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 17:48 UTC. This page is informational and not investment advice.